Jose Baselga, MD, PhD, FASCO, Memorial Sloan Kettering Cancer Center, presenting Abstract 1006, Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER, during Saturday Press Briefing